First Derivatives plc
First Derivatives occupies a niche position within the market place offering a combination domain knowledge of financial markets and expertise in financial services technologies. We provide innovative trading platforms for low latency, high volume environments across all asset classes including FX, equity, fixed income and commodities - providing credit, market, operational, liquidity, capital adequacy and stress testing solutions. The Company scopes, designs, develops, implements and supports a broad range of mission critical data and trading systems across front, middle and back-office operations.
Mr Jamie ConlonBusiness Development
Mr Gary ConnollyBusiness Development
Formuli is a Business Development and Licensing Agency that helps companies find partners for their technologies and products. At Bio Europe, Formuli is presenting the following opportunities for partnering:
1. A Potent Novel Anti-Inflammatory agent with an excellent efficacy/safety profile for use alone, or in combination with Steroids.
2. An Invisible Transdermal Spray-On patch technology focussing on ADHD, Alzheimers, Parkinsons and Pain, but with the potential for broad utility.
3. A Once Weekly Oral Tablet formulation of Aripiprazole for Bipolar Disorder, Schizophrenia and MDD.
4. A Blood Brain Barrier Transport Mechanism with excellent early results in NeuroOncology but with the potential for broad utility.
Dr Russ PendletonCEO
Fusion Antibodies Ltd
Fusion Antibodies is a high quality European CRO that offers a range of fee-for-service, royalty free technology services covering all stages of therapeutic development of Biopharmaceutical drugs- from discovery/preclinical to cell line development and clinical supply.
Our clients are global Japan, USA & Europe and include Academic, Biotech’s and most of the top 10 pharmaceutical companies.
Four antibodies which have been produced using Fusion Antibodies technologies are currently being progressed through clinical development.
At BioEurope, Fusion Antibodies showcases our next generation CDRx Antibody Humanization Platform (www.fusionantibodies.com/humanization) converting Mouse, Rat, Rabbit and Llama antibodies into high expressing, functional humanized antibody lead drug candidates.
CDRx platform Humanization Key points
• Next generation in silico Antibody Humanization platform
• Improvements over traditional CDR grafting methods
• T-Cell epitope screening and avoidance included in the design stage
• 3D structural predictions included
• No Royalty Fee
• 15 years experience of Antibody drug development
• Humanized variants that can be named with the suffix –“tuzumab” under the International Nonproprietary Names (INN) Programme as governed by the WHO
• Humanized variants selected for manufacturability and expression
• Stable cell expression with CHOvolution cell line capable of up to 7g per litre
• 4 humanized antibodies entering the clinic in 16/17
• More than 60 humanization projects completed worldwide for large pharma, mid-size and biotechs in the past 5 years in Japan, USA & Europe.
We look to partner with companies interested in developing high quality antibody drugs. We also offer a range of cell line development services (https://www.fusionantibodies.com/CLD) and have the associated expertise and partners to deliver a high quality CHO cell line expression for your protein of interest from proof-of-concept to cGMP. Fusion Antibodies also specialize in high quality monoclonal antibodies (particularly those which are difficult to produce), Antibody Sequencing and other Antibody engineering project (scFv, F(ab), Bi-Specifics). We have the capacity to act as a 1-stop shop, guiding your project from discovery to validation in the clinic.
Summary Fusion Antibodies services
cGMP ready CHO cell line development
Manufacture of Biopharmaceuticals for Phase I, II and III clinical studies
With 15+ years of experience in the antibody drug research industry and >60 antibody humanization projects with multiple candidates now in the clinic.
Fusion Antibodies is the 1st choice for accelerating your antibody research towards the clinic.
Let us make your idea a clinical ready drug Asset!